GlassScriptPhysician profile
Dan A Miller
NPI 1063894731
$3,324.73
in general payments reported to CMS, 2019-2025
22 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $640 · 2023: $951 · 2024: $636 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $944.11 | 2021-2025 | |
| Novo Nordisk INC | $347.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $321.33 | 2023-2025 | |
| Amgen INC. | $266.77 | 2021-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $232.95 | 2021-2024 | Breztri |
| Lilly USA, LLC | $226.70 | 2021-2025 | Emgality, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $177.14 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $161.18 | 2021-2024 | |
| Glaxosmithkline, LLC. | $136.94 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $134.38 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $53.81 | 2021 | |
| Seqirus USA INC | $49.84 | 2025 | Flucelvax, Fluad |
| Amarin Pharma, INC. | $34.82 | 2021 | |
| Braeburn INC. | $33.13 | 2024 | Brixadi |
| Adlon Therapeutics L.P. | $31.50 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.58 | 2022-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $29.50 | 2023 | Auvelity |
| Indivior INC. | $26.12 | 2023 | Sublocade |
| Optinose US, INC. | $25.44 | 2025 | |
| Abbott Laboratories | $23.20 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $22.58 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $16.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.